Union City

Researchers are conducting a prospective multi-center observational study in the United States to improve and evaluate a panel of biomarkers found in plasma circulating free-DNA (cfDNA) for detecting colorectal cancer (CRC) and advanced adenomas. The study focuses on individuals either suspected to have advanced adenomas, newly diagnosed with CRC scheduled for surgery, or those at average risk undergoing routine colonoscopy screening. The aim is to optimize the biomarker panel and assess its diagnostic performance. Participants will provide blood samples, up to 40 ml, during study visits. The study collects clinical data alongside these samples from two groups: those with suspected advanced adenomas or newly diagnosed CRC awaiting surgery, and average-risk individuals scheduled for screening colonoscopy. The main intervention involves evaluating the preliminary cfDNA biomarker panel to support CRC and advanced adenoma detection. During the study, participants will undergo blood sample collection and clinical data collection. Researchers will analyze plasma cfDNA markers within 12 months of sample collection to evaluate their effectiveness. Participants must provide informed consent and comply with study requirements. The study monitors participant eligibility carefully and excludes those with certain medical histories or conditions. The study includes adults aged 45 to 84 years and involves follow-up through standard screening procedures and sample testing.